Jefferies Adjusts Price Target#
Jefferies has lowered its price target for HCA Healthcare Inc. (NYSE:HCA) from $590 to $525, while still maintaining a Buy rating on the stock. Currently, HCA shares are trading at $432.46, which is below the average target set by analysts, ranging from $425 to $635.
Weather's Impact on Patient Volumes#
The firm attributed this adjustment to challenging conditions as the weather affected patient admissions. Specifically, ice storms in January resulted in a 0.3% decrease in same-store admissions. Additionally, weak revenues from respiratory services contributed to a further 0.7% decline in performance. This shortfall in revenue led to a de-leveraging effect, causing HCA to miss its EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) expectations. Over the past twelve months, HCA generated $15.49 billion in EBITDA, trading at an EV/EBITDA (Enterprise Value to EBITDA) multiple of 9.5 times.
Mixed Financial Performance#
In its recent earnings report for the first quarter of 2026, HCA Healthcare showed a mixed financial performance. The company slightly exceeded earnings and revenue forecasts, posting earnings per share (EPS) of $7.15, just above the expected $7.14. Revenue for the quarter reached $19.11 billion, surpassing projections by $200 million. However, despite these positive results, HCA's stock saw a decline in premarket trading, reflecting ongoing concerns among investors regarding operational challenges and market conditions.
Future Outlook#
Jefferies remains optimistic about HCA, citing upcoming approvals for strategic development projects, expected cost savings, and productivity improvements from the company's resiliency program. Additionally, HCA is noted to have a strong free cash flow, currently yielding 8%, with a price-to-earnings (P/E) ratio of 15.3 times. Investors are closely monitoring how HCA will navigate these challenges in the coming quarters.